UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 1319, 2010

TIENS BIOTECH GROUP (USA), INC.

(Exact name of registrant as specified in its charter)

Delaware	001-32477	75-2926439
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)
of incorporation)		Identification Number)

No. 6, Yuanquan Road, Wuqing New-Tech Industrial Park, Tianjin, China 301700

(Address of principal executive offices)

Registrant's telephone number, including area code:（ (86）) 22-8213-~~7335~~7658

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item 5.02 Departure of~~o ~~Directors~~Soliciting ormaterials ~~Certain~~pursuant ~~Officers;~~to ~~Election~~Rule of14a-12 ~~Directors;~~under ~~Appointment~~the ofExchange ~~Certain Officers;~~Act ~~Compensatory~~(17 ~~Arrangements~~CFR ~~of Certain Officers~~240.14a-12)

Ono ~~August 13,~~Pre-commencement ~~2010,~~communications ~~the~~pursuant ~~Board~~to ofRule ~~Directors of Tiens Biotech Group~~ 14d-2(~~USA~~b), ~~Inc.~~under (the ~~“Company”)~~ ~~appointed~~Exchange ~~Jinyuan~~Act Li, Chairman, Chief Executive Officer and President of the Company, as Acting Chief Financial Officer of the Company to fill the vacancy created by the resignation of Manbo He, the Company’s former Chief Financial Officer, who resigned on June (17, ~~2010~~CFR 240.14d-2(b))

~~Other information~~o ~~required~~Pre-commencement bycommunications ~~this~~pursuant ~~Item~~to ~~regarding~~Rule ~~Mr.~~13e-4(c) Liunder isthe ~~omitted,~~Exchange asAct it(17 ~~has~~CFR ~~been previously reported~~240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On August 19, 2010, Tiens Biotech Group (USA), Inc. (the “Company”) issued a press release reporting the Company’s financial results for the fiscal quarter ended June 30, 2010. The full text of the press release is set forth in Exhibit 99.1 attached hereto.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit Number

Description

99.1

Press release, dated August 19, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TIENS BIOTECH GROUP (USA), INC.
Date: August 17, 2010	By:	/s/ Jinyuan Li
Date: August 19, 2010	By:	/s/ Jinyuan Li
		Name: Jinyuan Li
		Title: Chairman, Chief Executive Officer and President
		Title: Chief Executive Officer

Exhibits

Exhibit Number		Description

99.1		Press release, dated August 19, 2010.

Filing Compare · TIENS BIOTECH GROUP USA INC